Novo Nordisk A/S
Mounjaro is more effective than Ozempic for weight loss in overweight and obese adults, real world study says
A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, May 29, 2023. George Frey | Reuters The blockbuster diabetes drug Mounjaro is more effective for weight loss than another highly popular treatment, Ozempic, in overweight or […]
Read More
Health care, AI and far more: How a single professional is investing for a ‘Goldilocks’ economic climate
Uncertainty in world-wide marketplaces coupled with persistently superior inflation has elevated the problem no matter whether there will be a tricky or a soft economic landing. Andy Budden, financial commitment director for equities at international monetary services agency Money Team, is in the latter camp and expects the U.S. Federal Reserve to maintain fees high […]
Read More
Hard cash is a ‘missed opportunity’ correct now, suggests one pro — here is where he’s investing as an alternative
The persistent uncertainty in economic markets, alongside with substantial curiosity premiums around the entire world, have raised the allure of keeping on to cash — but one equities qualified states this may perhaps not be the very best idea. “We are at a issue in which money deposits or revenue in hard cash and revenue […]
Read More
Here’s what Wall Street is saying about obesity drug Wegovy following Novo Nordisk’s key study
Analysts are largely optimistic about a new class of anti-obesity medications following a landmark study released over the weekend. Novo Nordisk ‘s Select study of about 17,500 people found the use of its Wegovy decreased the risk of serious cardiovascular complications such as heart attacks. The study, which was shared at the American Heart Association […]
Read More
Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
CFOTO | Future Publishing | Getty Images As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer’s experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space’s dominant players Eli Lilly and Novo Nordisk. Those […]
Read More
Novo Nordisk’s weight loss drug Wegovy slashes risk of serious heart events
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Novo Nordisk’s Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely […]
Read More
Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here’s why, analyst says
Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? For Deutsche Bank analyst James Shin, the answer is: “yes, but not to this degree.” Shin initiated coverage of a host of pharmaceutical stocks, including Eli Lilly, on Wednesday. The analyst said he is worried Lilly’s valuation is “grating against fundamentals,” as […]
Read More
FDA approves Eli Lilly’s tirzepatide for weight loss, paving way for wider use of blockbuster drug
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, on March 29, 2023. George Frey | Reuters The Food and Drug Administration on Wednesday approved Eli Lilly‘s blockbuster drug tirzepatide for weight loss, paving the way for […]
Read More
The Ozempic effect has battered this weight loss stock, but Morgan Stanley says it’s a top pick
Game-changing anti-obesity medications have posed nothing short of an existential crisis for Weight Watchers parent WW International since they arrived on the scene, but CEO Sima Sistani has been confronting this challenge head-on. Despite an 11% dive in the stock Friday, Morgan Stanley said it thinks the company “has gone through an incredible transformation over […]
Read More
Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month
Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. Michael Siluk | UCG | Getty Images Novo Nordisk on Thursday said 80% of U.S. patients with insurance coverage who take its highly popular weight loss treatment […]
Read More